How can insurers justify spending hundreds of thousands of dollars per patient per year on "orphan drugs" - extremely expensive medications for rare conditions that are mostly chronic and life-threatening -- when this money could provide greater overall health benefit if spread out among many other patients?

How can insurers justify spending hundreds of thousands of dollars per patient per year on "orphan drugs" – extremely expensive medications for rare conditions that are mostly chronic and life-threatening -- when this money could provide greater overall health benefit if spread out among many other patients? Those spending decisions ...

(The Hastings Center) Can insurers justify spending hundreds of thousands of dollars per patient per year on "orphan drugs" - extremely expensive medications for rare conditions that are mostly chronic and life-threatening -- when this money could provide greater overall health benefits to many other patients? Those spending decisions ...

Orphan drug development has become more feasible than in previous years but we've barely scratched the surface: only 367 approved orphan drugs out of 6,800 rare diseases. We need to keep the momentum going. Come April 10-13, over 300 key decision makers from orphan drug manufacturers, patient groups, payers ...

Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris' investigational drug, chlormethine gel, for the treatment of Cutaneous T-Cell Lymphoma.

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B.

Children who experience the stress of separation at birth from biological parents and are brought up in orphanages undergo biological consequences such as changes in their genome functioning, Yale School of Medicine researchers report in a new study. Published online in the current issue of Development and Psychopathology, the study ...

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived ...

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

The U.S. Food and Drug Administration (FDA) has given orphan drug designation to Provectus Pharmaceuticals, Inc., for Rose Bengal, the active component in their new oncology medication PV-10. The drug is designed for the treatment of hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. At present Provectus is ...

(Digna Biotech S.L) Biotechnological company Digna Biotech announced that the Food and Drug Administration granted cardiotrophin-1 Orphan Drug status for use in the treatment of acute liver failure.

Digna Biotech, a Spanish biotechnological company, announces that the Food and Drug Administration (FDA) granted cardiotrophin-1 (CT-1) Orphan Drug status for use in the treatment of acute liver failure (Designation request 11-3507). This provides more incentives to work on cures for this disease, which has an ...